Pan Cancer T is a fully independent biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands, dedicated to discovering and developing innovative T cell receptor (TCR) T cell therapeutics. TCR-T is a credible and validated modality that has the potential to induce deep and durable cancer remissions, typically from a single infusion. Pan Cancer T’s strategy tackles two major obstacles preventing TCR-T therapies to expand to the main solid cancer types: clean and immunogenic new targets to expand to solid tumour types that are not (sufficiently) accessible today and overcoming the tumour-induced immune inhibition. Pan Cancer T addresses both challenges into one “dual acting” approach and addresses perhaps the greatest challenge faced by TCR-T companies, namely the ability to consistently and reproducibly achieve robust clinical efficacy across different tumour types and cohorts therein:

- We believe that identifying the right targets is one of the most important prerequisites for an effective and safe therapy. Pan Cancer T has a portfolio of 30 untapped tumor selective target that are shared by large patient cohorts.

- Evading antitumour immunity is a hallmark for the development and progression of cancer. We believe that the TME-induced immune suppression is a key contributor for the duration of responses. Hence, we arm our T cells against the tumour type specific immune deficits.

We have discovered, characterized and are developing a TCR-T against a novel druggable target (“PCT-1”) that is abundantly expressed with strong homogeneity in ~85% of patients with triple negative breast cancer (TNBC), a deadly form of breast cancer with clear unmet need for novel therapeutic approaches. We have developed preclinical proof of concept and aim to advance the program to the clinic. The company has the ambition to, as a next step, exploit other targets, other solid tumors and other TME solutions.

свернуть